<DOC>
	<DOCNO>NCT01906879</DOCNO>
	<brief_summary>Whether non-bismuth quadruple therapy ( concomitant therapy ) effective bismuth quadruple therapy triple therapy 14 day remain unknown . Therefore , aim compare eradication rate long term re-infection rate quadruple therapy 10 day versus non-bismuth quadruple therapy 10 day vs. triple therapy 14 day . Methods : This multi-center , open label , randomize control trial Patients : H. pylorus infect patient willingness receive eradication therapy Testing H. pylorus infection Before First Line Ttreatment ( 1 ) Any two positive rapid urease test , histology , serology culture positive UBT consider H. pylorus infect After First Line Treatment : C13-Urea breath test use ass existence H. pylori 6-8 week first line therapy . Long term reinfection : C13- Urea breath test use ass recurrence H. pylori 1 year eradication therapy</brief_summary>
	<brief_title>Triple Therapy Versus Quadruple Therapies First Line Therapy Helicobacter Pylori Infection</brief_title>
	<detailed_description>First line therapy : open label , randomize control trial , randomize one three group Group ( A ) : triple therapy 14 day D1-D14 : ( lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm ) bid Group ( B ) : non-bismuth quadruple therapy 10 day D1-D10 : lansoprazole 30mg bid + amoxicillin 1gm bid + clarithromycin 500mg bid + metronidazole 500mg bid Group ( C ) : bismuth quadruple therapy 10 day D1-D10 : lansoprazole 30mg bid + colloidal bismuth subcitrate 300mg tid + metronidazole 500mg tid + tetracycline 500mg tid Second line therapy : patient fail first line treatment rescue follow treatment Group ( A ) Patient fail triple therapy retreat bismuth quadruple therapy 10 day D1-D10 : lansoprazole 30mg bid + colloidal bismuth subcitrate 300mg tid + metronidazole 500mg tid + tetracycline 500mg tid Group ( B ) Patient fail non-bismuth quadruple therapy retreat bismuth quadruple therapy 10 day D1-D10 : lansoprazole 30mg bid + colloidal bismuth subcitrate 300mg tid + metronidazole 500mg tid + tetracycline 500mg tid Group ( C ) Patients fail bismuth quadruple therapy retreat non-bismuth quadruple therapy 10 day D1-D10 : lansoprazole 30mg bid + amoxicillin 1gm bid + clarithromycin 500mg bid + metronidazole 500mg bid</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Helicobacter Infections</mesh_term>
	<mesh_term>Bismuth</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>Patients age great 20 year H. pylori infection without prior eradication therapy willing receive sequential therapy eligible enrolment . Written inform consent obtain patient prior enrollment . Patients exclude study one follow criterion present : ( 1 ) child teenager age less 20 year , ( 2 ) history gastrectomy , ( 3 ) gastric malignancy , include adenocarcinoma lymphoma , ( 4 ) previous allergic reaction antibiotic ( amoxicillin , clarithromycin , metronidazole , levofloxacin ) prompt pump inhibitor ( lansoprazole ) , ( 5 ) contraindication treatment drug , ( 6 ) pregnant lactate woman , ( 7 ) severe concurrent disease , ( 8 ) Patients give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>